by Peter Kaiser, MD
Peter Kaiser, MD, a surgeon at the Cole Eye Institute in Cleveland, discusses his long-term outcomes of subgroup analysis from the Thrombogenic phase 3 studies with ocripasmin as it relates to macular holes.
1,332 video views and 24,244 series views since 8/29/2011
-
Inherited Retinal Diseases
-
Thrombogenic Phase 3 Ocriplasmin Study
-
Achieving Water-tight Sclerotomies after 23G Surgery
-
PACORES Update
-
Sclerally-fixated IOLs Without Sutures
-
Does Suturing 23-Gauge Sclerotomies Reduce Postop Vitreous Hemorrhage in Di…
-
Modified Probe for Small-gauge Vitrectomy
-
The Role of Scissors in Diabetic Traction Retinal Detachment Surgery
-
Fine Needle Aspiration Biopsy
-
Adjunctive Steroids for Small-gauge Vitrectomy
-
COPERNICUS
-
Ranibizumab Variable Dosing: Horizon Extension Data
-
Dexamethasone Implant Plus Laser vs Laser Monotherapy
-
Ocriplasmin Phase 3 Data
-
Pneumatic Retinopexy, Pars Plana Vitrectomy, and Scleral Buckling
-
FAME Subanalyses
-
DA VINCI
-
Allen Ho, MD, Reviews Highlights of Upcoming Retina Meeting
-
Dean Eliott, MD, Reviews Highlights of Upcoming Retina Meeting
